Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Single agent chemotherapy with doxorubicin for feline lymphoma: a retrospective study of 19 cases (1994-1997).

Tytuł :
Single agent chemotherapy with doxorubicin for feline lymphoma: a retrospective study of 19 cases (1994-1997).
Autorzy :
Kristal O; Tufts University, School of Veterinary Medicine, North Grafton, MA 01536, USA.
Lana SE
Ogilvie GK
Rand WM
Cotter SM
Moore AS
Pokaż więcej
Źródło :
Journal of veterinary internal medicine [J Vet Intern Med] 2001 Mar-Apr; Vol. 15 (2), pp. 125-30.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: <2010-> : Malden, MA : Wiley Periodicals
Original Publication: Philadelphia : J.B. Lippincott Co., [c1987-
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Cat Diseases/*drug therapy
Cat Diseases/*mortality
Doxorubicin/*therapeutic use
Lymphoma/*veterinary
Animals ; Antineoplastic Agents/administration & dosage ; Cats ; Doxorubicin/administration & dosage ; Drug Administration Schedule ; Female ; Infusions, Intravenous/veterinary ; Lymphoma/drug therapy ; Lymphoma/mortality ; Male ; Records/veterinary ; Retrospective Studies ; Survival Rate
Substance Nomenclature :
0 (Antineoplastic Agents)
80168379AG (Doxorubicin)
Entry Date(s) :
Date Created: 20010413 Date Completed: 20010628 Latest Revision: 20190513
Update Code :
20210210
DOI :
10.1892/0891-6640(2001)015<0125:sacwdf>2.3.co;2
PMID :
11300595
Czasopismo naukowe
Medical records of 21 cats with confirmed lymphoma treated with single-agent doxorubicin were reviewed. Nineteen cats met the inclusion criteria for this retrospective study. Doxorubicin was given at a dosage of 25 mg/m2 (n = 8) or 1 mg/kg (n = 11) IV, every 3 weeks for a total of 5 treatments. Four of 16 tested cats were positive for feline leukemia virus (FeLV) and all 16 cats tested negative for feline immunodeficiency virus. Eight of the 19 cats (42%) responded to doxorubicin for a median duration of 64 days (range, 35-575 days). Five cats (26%) achieved a complete response (CR) to doxorubicin for a median duration of 92 days (range, 54-575 days). Partial response was observed in 3 cats. Institution was the only significant prognostic indicator for response, with cats treated at Colorado State University being more likely to achieve CR than cats treated at Tufts University. Cats that achieved CR to doxorubicin and FeLV-negative cats had significantly longer survival times. Loss of appetite was the most common toxicity, observed in 9 cats (47%), and was severe in 5 cats (26%). Other toxicoses were less frequent and included vomiting, diarrhea, and myelosuppression. Doxorubicin was not very effective at inducing and maintaining remission in the cats in this study. Therefore, if doxorubicin is used for the treatment of feline lymphoma, it should be combined with other effective chemotherapeutic drugs in a combination protocol.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies